Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

What is the Mechanism of Progression with Trastuzumab Treatment - Escape or Resistance?

  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Human epidermal growth factor receptor (HER) 2 overexpression, observed in 20-25 percent of invasive breast cancers, is well known to be associated with a more aggressive phenotype and poor prognosis, with resistance to certain chemotherapeutic agents. The majority of patients with metastatic breast cancer who initially respond to trastuzumab, demonstrate disease progression within 1 year of treatment initiation. Furthermore, lack of response in some patients and relapse during the course of therapy, continue to challenge researchers and clinicians. A better understanding of the fundamental mechanisms of trastuzumab action is required so that new therapies directed at HER2 can be developed. We present here findings for mechanisms, both of Trastuzumab action and clinical resistance or escape.

Keywords

References

  1. Adams CW, Allison DE, Flagella K, et al (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology -Immunotherapy, 55, 717-7. https://doi.org/10.1007/s00262-005-0058-x
  2. Bailey TA, Luan H, Clubb RJ, et al (2011). Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinogenesis, 10, 8. https://doi.org/10.4103/1477-3163.78271
  3. Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 18, 633-0.
  4. Baselga J, Cortes J, Kim SB, et al (2011). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England J Med, 366, 109-9
  5. Gianni L, Pienkowski T, Im YH, et al. (2011). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncology, 13, 25-2
  6. Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clinical Oncology, 23, 4265-4. https://doi.org/10.1200/JCO.2005.04.173
  7. Montemurro F, Valabrega G, Aglietta M (2007). Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 7, 257-8. https://doi.org/10.1517/14712598.7.2.257
  8. Nahta R, Hung MC, Esteva FJ (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 64, 2343-6. https://doi.org/10.1158/0008-5472.CAN-03-3856
  9. Ross JS, Slodkowska EA, Symmans WF, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-8. https://doi.org/10.1634/theoncologist.2008-0230
  10. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England J Med, 344, 783-2. https://doi.org/10.1056/NEJM200103153441101
  11. Tortora, G (2011). Mechanisms of Resistance to HER2 Target Therapy. J National Cancer Institute, 95-8.
  12. Tovey SM, Witton CJ, Bartlett JM, et al (2004). Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast cancer Res, 6, 246-1. https://doi.org/10.1186/bcr936
  13. Wu Y, Amonkar MM, Sherrill BH, et al (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Eur Society for Med Oncology, 22, 2582-90.

Cited by

  1. Effect of Botulinum Toxin A on Proliferation and Apoptosis in the T47D Breast Cancer Cell Line vol.14, pp.2, 2013, https://doi.org/10.7314/APJCP.2013.14.2.891
  2. Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6425
  3. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4127
  4. in HER2-positive breast cancer cells vol.39, pp.6, 2017, https://doi.org/10.1177/1010428317707374